Management of cardiovascular disease in aging persons with haemophilia

Roger E. G. Schutgens; Michiel Voskuil; Evelien P. Mauser-Bunschoten

doi:10.5482/HAMO-16-09-0037

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2017; 37(03): 196-201
DOI: 10.5482/HAMO-16-09-0037

State of the art

Schattauer GmbH

Management of cardiovascular disease in aging persons with haemophilia

Management von kardiovaskulären Erkrankungen bei älteren Patienten mit Hämophilie

Autoren

Roger E. G. Schutgens

¹Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands
Michiel Voskuil

²Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
Evelien P. Mauser-Bunschoten

¹Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands

Abstract

Summary

With the aging of the haemophilia population, age related comorbidities become more and more a medical issue. Managing haemophilia patients with cardiovascular disease is a difficult task for many haemophilia-treating physicians. Over the years, insights on prevalence, risk factors and management of cardiovascular disease in haemophilia have improved substantially. It is now recognised that many risk factors, such as hypertension and overweight, occur quite frequently in patients with haemophilia. Several new insights in anticoagulation management of atrial fibrillation and coronary ischaemia in haemophilia have been suggested. This review provides an general overview of the current knowledge of these topics in literature.

Zusammenfassung

Mit zunehmendem Alter werden auch bei Patienten mit Hämophilie altersbedingte Begleitkrankheiten mehr und mehr zum medizinischen Problem. Die Therapie von Hämophilie-Patienten mit einer Herzkreislaufkrankheit ist eine schwierige Aufgabe für die behandelnden Ärzte. Mit den Jahren hat sich das Wissen über Prävalenz, Risikofaktoren und Therapie kardiovaskulärer Krankheiten bei Hämophilie erheblich verbessert. Man weiß heute, dass viele Risikofaktoren wie Hypertonie und Übergewicht recht häufig bei Patienten mit Hämophilie auftreten. Es gibt eine Reihe neuer Ansätze zur Antikoagulationsbehandlung bei Vorhofflimmern und koronarer Ischämie für Hämophilie-Patienten. In dieser Übersichtsarbeit geben wir einen allgemeinen Überblick über den derzeitigen Wissensstand zu diesen Themen in der Literatur.

Keywords

haemophilia - cardiovascular - anticoagulation

Schlüsselwörter

Hämophilie - kardiovaskulär - Antikoagulation

Volltext

Referenzen

References
1 Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC. et al. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 07 (02) 247-254.
2 Fransen DEvan de Putte, Fischer K, Makris M. et al. History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. Eur J Haematol 2012; 89 (04) 336-339.
3 Minuk L, Jackson S, Iorio A. et al. Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia 2015; 21 (06) 736-741.
4 Wang JD, Chan WC, Fu YC. et al. Prevalence and risk factors of atherothrombotic events among 1054 hemophilia patients: a population-based analysis. Thromb Res 2015; 135 (03) 502-507.
5 Jolley RJ, Quan H, Jette N. et al. Validation and optimisation of an ICD-10-coded case definition for sepsis using administrative health data. BMJ Open 2015; 05 (12) e009487.
6 Talia J, Agarwal S, Momoh AO. et al. The validity of hospital discharge data for autologous breast reconstruction research. Plast Reconstr Surg 2015; 135 (02) 368-374.
7 Tuinenburg A, Rutten A, Kavousi M. et al. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32 (03) 799-804.
8 Biere-Rafi S, Tuinenburg A, Haak BW. et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost 2012; 10 (01) 30-37.
9 Sousos N, Gavriilaki E, Vakalopoulou S, Garipidou V. Understanding cardiovascular risk in hemophilia: A step towards prevention and management. Thromb Res 2016; 140: 14-21.
10 Fransen DEvan de Putte, Fischer K, Makris M. et al. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost 2013; 109 (01) 16-23.
11 Wong TE, Majumdar S, Adams E. et al. Overweight and obesity in hemophilia: a systematic review of the literature. Am J Prev Med 2011; 41 (6 Suppl 4): S369-375.
12 Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005; 331 7517 614.
13 Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood 2014; 123 (09) 1297-1301.
14 Schutgens RE, Klamroth R, Pabinger I. et al. Management of atrial fibrillation in people with haemophilia – a consensus view by the ADVANCE Working Group. Haemophilia 2014; 20 (06) e417-420.
15 Chantarangkul V, Clerici M, Bressi C. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyperor hypo-coagulability. Haematologica 2003; 88 (05) 547-554.
16 De Koning FKMLY, de Laat B, Huisman A. et al. Comparing thrombin generation in patients with haemophilia A and patients on vitamin K antagonists. J Thromb Haemost 2015; 13: 316.
17 Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128 (02) 178-184.
18 Schutgens RE, Tuinenburg A, Fischer K, Mauser-Bunschoten EP. Anticoagulation therapy in haemophilia. Managing the unknown. Hamostaseologie 2013; 33 (04) 299-304.
19 Schutgens REG, van der Heijden JF, Mauser-Bunschoten EP, Mannucci PM. New concepts for anticoagulant therapy in persons with hemophilia. Blood 2016; 128 (20) 2471-2474.
20 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18) 2370-2375.
21 Schutgens RE, Klamroth R, Pabinger I. et al. Atrial fibrillation in patients with haemophilia: a crosssectional evaluation in Europe. Haemophilia 2014; 20 (05) 682-686.
22 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747.
23 Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114 (26) 5256-5263.
24 Schutgens RE, Tuinenburg A, Roosendaal G. et al. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15 (04) 952-958.
25 Tuinenburg A, Damen SA, Ypma PF. et al. Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline. Haemophilia 2013; 19 (03) 370-377.
26 Ferrante G, Rao SV, Juni P. et al. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv 2016; 09 (14) 1419-1434.
27 de Raucourt E, Roussel-Robert V, Zetterberg E. Prevention and treatment of atherosclerosis in haemophilia – how to balance risk of bleeding with risk of ischaemic events. Eur J Haematol 2015; 94 (Suppl. 77) 23-29.
28 Staritz P, de Moerloose P, Schutgens R. et al. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia – an assessment by the ADVANCE Working Group. Haemophilia 2013; 19 (06) 833-840.
29 Windecker S, Kolh P, Alfonso F. et al. [2014 ESC/ EACTS Guidelines on myocardial revascularization]. Kardiol Pol 2014; 72 (12) 1253-1379.
30 Bangalore S, Kumar S, Fusaro M. et al. Short and long-term outcomes with drug-eluting and baremetal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of followup from randomized trials. Circulation 2012; 125 (23) 2873-2891.
31 Valgimigli M, Patialiakas A, Thury A. et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65 (08) 805-815.
32 Fogarty PF, Mancuso ME, Kasthuri R. et al. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia 2015; 21 (05) 589-597.
33 Yeung CH, Santesso N, Pai M. et al. Care models in the management of haemophilia: a systematic review. Haemophilia 2016; 22 (Suppl. 03) 31-40.
34 Pai M, Key NS, Skinner M. et al. NHF-McMaster Guideline on Care Models for Haemophilia Management. Haemophilia 2016; 22 (Suppl. 03) 6-16.